Nuvation Bio Inc.

What they do

Nuvation Bio is a global oncology company developing and commercializing small-molecule therapies. Its sole approved product, IBTROZI (taletrectinib), is launched in the U.S. for ROS1+ NSCLC and marketed by partners in Japan (Nippon Kayaku) and China (Innovent). The pipeline includes safusidenib, an investigational mIDH1 inhibitor in Phase 3 for IDH1-mutant astrocytoma, and other earlier-stage programs.

Revenue drivers

• IBTROZI (taletrectinib) U.S. net product revenue — Only approved product; Q2 2026 net product revenue was $23.2 million, representing 25% QoQ growth and the majority of the $31.7 million total quarterly revenue.
• Partner commercialization in Japan and China — Nippon Kayaku commercializes taletrectinib in Japan under IBTROZI and Innovent in China under DOVBLERON; revenue from these partners contributes to total revenue via collaboration or license payments.
• Eisai partnership for Europe and other territories — In January 2026, announced a partnership with Eisai to commercialize taletrectinib in Europe and other territories outside the U.S., China, and Japan; Eisai's MAA validated by EMA and UK MHRA, potentially leading to future milestone or royalty revenue.

Recent performance

For Q2 2026, Nuvation Bio reported total revenue of $31.7 million, including $23.2 million in net product revenue for IBTROZI. Total revenue increased from $13.1 million in Q3 2025 to $83.2 million in Q1 2026, then fell to $31.7 million in Q2 2026. Annual revenue rose from zero in 2023 to $7.9 million in 2024 and $62.9 million in 2025, driven by the IBTROZI launch launched in June 2025. Net loss for 2025 was $204.6 million, and cash, cash equivalents, and marketable securities were $661.0 million as of June 30, 2026.

Strategy

Nuvation Bio is focused on expanding IBTROZI's adoption in the U.S., particularly in TKI-naive patients, supported by long-term efficacy data from TRUST-I. The company is also expanding safusidenib's clinical program to broader IDH1-mutant glioma populations, including a Phase 3 study outside the U.S. and a Phase 2 study post-vorasidenib. Management is building a commercial infrastructure and leveraging partnerships (Eisai, Nippon Kayaku, Innovent) for global reach. A July 2026 underwritten public offering of $287.5 million in convertible notes (plus $36.5 million from overallotment) was completed to strengthen the balance sheet.

Risks

• Commercial execution risk for IBTROZI — The company has limited commercial experience and its near-term revenue depends on successful U.S. commercialization; failure to gain market acceptance could materially harm results.
• Competition from other ROS1 TKIs — Superior or more cost-effective competitor products could reduce IBTROZI's market opportunity and limit revenue.
• Reimbursement and pricing pressure — Government and private payor coverage and reimbursement policies may not adequately support IBTROZI pricing, limiting sales.
• Dependence on clinical trial outcomes — Development of safusidenib and other pipeline candidates is subject to clinical trial success; failures could require significant additional capital and delay future growth.

Outlook

Management expects continued IBTROZI growth, with approximately 85% of new patient starts in Q2 2026 being TKI-naive and a 30% QoQ growth in that setting. The FDA has accepted the supplemental NDA for IBTROZI with updated data, with a target action date of January 4, 2027. Safusidenib trials are planned to initiate in 2026, and the Eisai partnership may lead to European approvals. The company believes its cash position supports ongoing investments in commercialization and pipeline expansion.